Fulcrum Therapeutics, Inc.
FULC
$3.52
$0.082.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.64% | 7.83% | |||
| Gross Profit | 8.64% | -7.83% | |||
| SG&A Expenses | 11.34% | -3.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.23% | 3.82% | |||
| Operating Income | 2.23% | -3.82% | |||
| Income Before Tax | 7.10% | -3.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.10% | -3.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.10% | -3.77% | |||
| EBIT | 2.23% | -3.82% | |||
| EBITDA | 2.23% | -3.88% | |||
| EPS Basic | 19.80% | 1.25% | |||
| Normalized Basic EPS | 19.82% | 1.23% | |||
| EPS Diluted | 20.34% | 0.58% | |||
| Normalized Diluted EPS | 19.82% | 1.23% | |||
| Average Basic Shares Outstanding | 15.86% | 5.09% | |||
| Average Diluted Shares Outstanding | 15.86% | 5.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||